HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winegar, D. A. Articles by Hansen, B. C. Search for Related Content PubMed PubMed Citation Articles by Winegar, D. A. Articles by Hansen, B. C. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 42, 1543-1551, October 2001
Copyright © 2001 by Lipid Research, Inc.

Original Article

Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Correspondence to: Deborah A. Winegar, To whom correspondence should be addressed., daw17189{at}gsk.com (E-mail)

Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, nondiabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity.

These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C. — Winegar, D. A., P. J. Brown, W. O. Wilkison, M. C. Lewis, R. J. Ott, W. Q. Tong, H. R. Brown, J. M. Lehmann, S. A. Kliewer, K. D. Plunket, J. M. Way, N. L. Bodkin, and B. C. Hansen. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J. Lipid Res. 2001. 42: 1543–1551.

Supplementary key words: fibrate, PPAR, triglyceride-lowering, HDL-C, apolipoprotein C-III

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Tsunoda, N. Kobayashi, T. Ide, M. Utsumi, M. Nagasawa, and K. Murakami A novel PPAR{alpha} agonist ameliorates insulin resistance in dogs fed a high-fat diet Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E833 - E840. [Abstract] [Full Text] [PDF]

				A. Kharitonenkov, V. J. Wroblewski, A. Koester, Y.-F. Chen, C. K. Clutinger, X. T. Tigno, B. C. Hansen, A. B. Shanafelt, and G. J. Etgen The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21 Endocrinology, February 1, 2007; 148(2): 774 - 781. [Abstract] [Full Text] [PDF]

				S. Serisier, F. Briand, K. Ouguerram, B. Siliart, T. Magot, and P. Nguyen Fenofibrate Lowers Lipid Parameters in Obese Dogs J. Nutr., July 1, 2006; 136(7): 2037S - 2040S. [Full Text] [PDF]

				J. P. Singh, R. Kauffman, W. Bensch, G. Wang, P. McClelland, J. Bean, C. Montrose, N. Mantlo, and A. Wagle Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor {alpha} Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression Mol. Pharmacol., September 1, 2005; 68(3): 763 - 768. [Abstract] [Full Text] [PDF]

				A. Reifel-Miller, K. Otto, E. Hawkins, R. Barr, W. R. Bensch, C. Bull, S. Dana, K. Klausing, J.-A. Martin, R. Rafaeloff-Phail, et al. A Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia Mol. Endocrinol., June 1, 2005; 19(6): 1593 - 1605. [Abstract] [Full Text] [PDF]

				H. K. Ortmeyer, Y. Adall, K. R. Marciani, A. Katsiaras, A. S. Ryan, N. L. Bodkin, and B. C. Hansen Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-{alpha} agonist (K-111) administration in rhesus monkeys Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1509 - R1517. [Abstract] [Full Text] [PDF]

				J. M. Wallace, M. Schwarz, P. Coward, J. Houze, J. K. Sawyer, K. L. Kelley, A. Chai, and L. L. Rudel Effects of peroxisome proliferator-activated receptor {alpha}/{delta} agonists on HDL-cholesterol in vervet monkeys J. Lipid Res., May 1, 2005; 46(5): 1009 - 1016. [Abstract] [Full Text] [PDF]

				M. Guzman, J. Lo Verme, J. Fu, F. Oveisi, C. Blazquez, and D. Piomelli Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor {alpha} (PPAR-{alpha}) J. Biol. Chem., July 2, 2004; 279(27): 27849 - 27854. [Abstract] [Full Text] [PDF]

				X. Prieur, H. Coste, and J. C. Rodriguez The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-{alpha} and Contains a Novel Farnesoid X-activated Receptor Response Element J. Biol. Chem., July 3, 2003; 278(28): 25468 - 25480. [Abstract] [Full Text] [PDF]

				C. L. Brand, J. Sturis, C. F. Gotfredsen, J. Fleckner, C. Fledelius, B. F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E841 - E854. [Abstract] [Full Text] [PDF]

				H. Coste and J. C. Rodriguez Orphan Nuclear Hormone Receptor Rev-erbalpha Regulates the Human Apolipoprotein CIII Promoter J. Biol. Chem., July 19, 2002; 277(30): 27120 - 27129. [Abstract] [Full Text] [PDF]